Clinical Trials
22 trialsNCT00611351 2023-10-23
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
Phase 2 Completed
NCT01165645 2022-12-01
Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma
Mayo Clinic
Phase NA Withdrawn
NCT00598169 2020-08-10
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
AIDS Malignancy Consortium
Phase 1 Completed
NCT01269385 2020-06-23
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
Mayo Clinic
Phase 1/2 Completed
NCT00691652 2019-11-27
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
OHSU Knight Cancer Institute
Phase 1/2 Terminated
NCT00387530 2019-08-02
Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
University of California, San Diego
Phase 2 Withdrawn
NCT01383447 2017-08-08
Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00049504 2017-05-17
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00509691 2017-05-09
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
University of Louisville
Phase 1 Completed
NCT00052520 2017-03-29
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00546377 2016-05-12
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01045928 2015-11-26
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00716911 2015-06-08
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
City of Hope Medical Center
Phase NA Completed
NCT00845104 2015-03-06
Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT00110071 2014-08-06
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00621452 2014-08-06
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00851552 2014-07-21
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00769613 2013-12-18
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00462657 2013-08-26
Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease
National Cancer Institute (NCI)
Phase NA Unknown
NCT00562068 2013-08-26
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00893477 2013-08-02
GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00896519 2013-08-02
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown